167.03

3.95% -6.855

Charles River Laboratories International Inc (CRL)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$173.89

Offen:

$170.56

24-Stunden-Volumen:

815.81K

Relative Volume:

0.85

Marktkapitalisierung:

$8.24B

Einnahmen:

$4.02B

Nettoeinkommen (Verlust:

$-142.16M

KGV:

-56.50

EPS:

-2.9563

Netto-Cashflow:

$518.49M

1W Leistung:

+4.57%

1M Leistung:

-4.26%

6M Leistung:

-4.53%

1J Leistung:

+22.01%

1-Tages-Spanne:

$161.53

$173.86

1-Wochen-Bereich:

$161.53

$179.83

52-Wochen-Spanne:

$91.86

$228.88

Charles River Laboratories International Inc Stock (CRL) Company Profile

Firmenname

Charles River Laboratories International Inc

Sektor

Healthcare (1117)

Branche

Diagnostics & Research (52)

Telefon

781-222-6000

Adresse

251 BALLARDVALE ST, WILMINGTON, MA

Mitarbeiter

19,700

Twitter

@criverlabs

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

CRL's Discussions on Twitter

Compare CRL vs TMO, DHR, IDXX, A, WAT

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CRL Charles River Laboratories International Inc	167.03	8.58B	4.02B	-142.16M	518.49M	-2.9563
TMO Thermo Fisher Scientific Inc	484.98	182.57B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	191.82	135.26B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	577.70	45.24B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	114.94	32.63B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	304.28	29.85B	3.17B	642.63M	516.49M	10.77

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-15	Hochstufung	BofA Securities	Neutral → Buy
2025-11-17	Hochstufung	Argus	Hold → Buy
2025-11-06	Hochstufung	Robert W. Baird	Neutral → Outperform
2025-10-06	Hochstufung	William Blair	Mkt Perform → Outperform
2025-10-02	Hochstufung	Barclays	Equal Weight → Overweight
2025-09-09	Hochstufung	Jefferies	Hold → Buy
2025-07-09	Hochstufung	Citigroup	Neutral → Buy
2025-05-23	Hochstufung	Redburn Atlantic	Neutral → Buy
2025-05-14	Hochstufung	TD Cowen	Hold → Buy
2025-05-08	Hochstufung	Evercore ISI	In-line → Outperform
2025-03-21	Herabstufung	Goldman	Buy → Neutral
2025-03-04	Hochstufung	Citigroup	Sell → Neutral
2025-03-03	Hochstufung	Redburn Atlantic	Sell → Neutral
2025-01-22	Herabstufung	William Blair	Outperform → Mkt Perform
2025-01-17	Herabstufung	UBS	Buy → Neutral
2024-11-18	Herabstufung	CLSA	Hold → Underperform
2024-11-07	Hochstufung	CLSA	Underperform → Hold
2024-10-23	Eingeleitet	CLSA	Underperform
2024-10-14	Eingeleitet	Redburn Atlantic	Sell
2024-10-07	Herabstufung	Evercore ISI	Outperform → In-line
2024-10-02	Herabstufung	BofA Securities	Buy → Neutral
2024-10-01	Herabstufung	Citigroup	Neutral → Sell
2024-08-08	Herabstufung	JP Morgan	Overweight → Neutral
2024-08-08	Herabstufung	Robert W. Baird	Outperform → Neutral
2024-06-28	Herabstufung	Argus	Buy → Hold
2024-06-07	Eingeleitet	Mizuho	Neutral
2024-06-06	Eingeleitet	Goldman	Buy
2024-02-15	Herabstufung	Guggenheim	Buy → Neutral
2023-09-13	Eingeleitet	TD Cowen	Market Perform
2023-07-10	Herabstufung	Citigroup	Buy → Neutral
2023-02-23	Hochstufung	Guggenheim	Neutral → Buy
2023-01-12	Herabstufung	Jefferies	Buy → Hold
2022-09-30	Hochstufung	Jefferies	Hold → Buy
2022-08-25	Eingeleitet	Credit Suisse	Outperform
2022-08-04	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2022-05-24	Eingeleitet	Guggenheim	Neutral
2022-04-25	Herabstufung	Jefferies	Buy → Hold
2022-04-07	Eingeleitet	Stephens	Overweight
2022-02-17	Bestätigt	BofA Securities	Buy
2022-02-17	Hochstufung	Citigroup	Neutral → Buy
2022-02-17	Bestätigt	Deutsche Bank	Buy
2022-02-17	Bestätigt	Morgan Stanley	Overweight
2022-02-17	Bestätigt	UBS	Buy
2021-08-05	Fortgesetzt	Credit Suisse	Neutral
2020-12-16	Herabstufung	Citigroup	Buy → Neutral
2020-09-10	Hochstufung	Jefferies	Hold → Buy
2020-07-01	Hochstufung	BofA Securities	Neutral → Buy
2020-05-13	Hochstufung	UBS	Neutral → Buy
2020-04-21	Herabstufung	Jefferies	Buy → Hold
2020-03-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-03-02	Eingeleitet	Deutsche Bank	Buy
2020-02-18	Hochstufung	Wolfe Research	Peer Perform → Outperform
2020-01-10	Hochstufung	Goldman	Neutral → Buy
2020-01-08	Eingeleitet	Wells Fargo	Overweight
2020-01-07	Eingeleitet	Citigroup	Buy
2019-10-18	Herabstufung	BofA/Merrill	Buy → Neutral
2019-06-10	Eingeleitet	SVB Leerink	Outperform
2019-04-30	Fortgesetzt	Evercore ISI	Outperform
2018-12-14	Eingeleitet	Deutsche Bank	Buy
2018-10-09	Eingeleitet	UBS	Neutral
2018-08-23	Hochstufung	Raymond James	Mkt Perform → Outperform
2018-07-17	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2018-06-15	Hochstufung	KeyBanc Capital Mkts	Sector Weight → Overweight
2018-02-14	Hochstufung	SunTrust	Hold → Buy

Alle ansehen

Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten

11:29 AM

NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX - Investing News Network

11:29 AM

08:55 AM

NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX – Company Announcement - Financial Times

08:55 AM

Apr 04, 2026

CRL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 04, 2026

Q3 2025 Charles River Laboratories International Inc Earnings Call Transcript - gurufocus.com

Apr 04, 2026

Lawson Kroeker Investment Management Inc. NE Sells 18,277 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat

Apr 04, 2026